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Abstract -  
Background: TAR DNA-binding protein-43 (TDP-43) proteinopathies are classified based upon the extent of 
modified TDP-43 and include a growing number of neurodegenerative diseases such as amyotrophic lateral sclerosis 
(ALS), frontotemporal lobar degeneration with ubiquitin immunoreactive, tau-negative inclusions (FTLD-U) and 
FTLD with motor neuron disease (FTLD-MND). 
 
Objective: The purpose of the study was to examine whether proteolytic modifications of TDP-43 are a relevant 
finding in Parkinson’s disease (PD) and dementia with Lewy Bodies (DLB). 
 
Methods:  A novel site-directed caspase-cleavage antibody, termed TDP caspase-cleavage product antibody 
(TDPccp), was utilized based upon a known caspase-3 cleavage consensus site within TDP-43 at position 219. 
 
Results: Application of this antibody to postmortem brain sections from PD and DLB revealed the presence of 
caspase-cleaved TDP-43 in Lewy bodies and Hirano bodies in all cases examined. Co-localization of TDPccp with 
an antibody to alpha-synuclein (α-Syn), which served as a general marker for Lewy bodies, was evident within the 
substantia nigra in both alpha-synucleinopathies. Interestingly, the TDPccp antibody detected a greater number of 
Lewy bodies in PD and DLB compared to the α-Syn antibody. In addition, a semi-quantitative analysis in both 
diseases confirmed this finding by indicating that the percent of caspase-cleaved TDP-43 single-labeled Lewy 
bodies was approximately twice the percent that of α-Syn labeling (in DLB 13.4% vs. 5.5%, while in PD 34.6% vs. 
17.6%, respectively). 
 
Conclusion: Collectively, these data have identified caspase-cleaved TDP-43 as a primary component of Lewy and 
Hirano bodies in PD and DLB, and suggest the TDPccp antibody is an effective marker for the detection of Lewy 
bodies in these neurodegenerative diseases. 
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Introduction- 
 
TAR DNA binding protein-43 (TDP-43) is a highly conserved 414 amino acid protein with an apparent molecular 
weight of approximately 43 kDa. It is ubiquitously expressed and appears to play a role in regulating RNA 
transcription and alternative splicing [1]. Findings from a recent study have also linked TDP-43 function to 
cytoskeletal stability and axonal transport by showing that TDP-43 regulates human neurofilament (hNFL) RNA 
stability [2].  
 
TDP-43 has been identified as a major component of ubiquitinated tau-negative inclusions in sporadic and familial 
FTLD-U and ALS [3]. A conspicuous finding in these studies was the presence of 25 and 35 kDa truncated 
fragments of TDP-43 in brain extracts from affected individuals that were not present in control subjects [3]. For this 
common pathology, these diseases were grouped together as a new entity of neurodegenerative disorders, classified 
as TDP-43 proteinopathies [4]. In addition, it has been recently reported that TDP-43 positive inclusions occur in 
other neurodegenerative disorders including brains of patients with argyrophilic grain disease, Alzheimer’s disease 
(AD), Lewy body related diseases, Pick’s disease and Huntington’s disease [5-11]. Current understanding suggests 
modifications to TDP-43 including hyperphosphorylation and proteolytic cleavage by caspases lead to a toxic gain 
of function. In particular, truncated TDP-43 redistributes from the nucleus to the cytoplasm [12] and this may 
promote cellular dysfunction by causing altered trafficking of the protein [13]. Therefore, post-translational 
proteolytic processing of TDP-43 by caspases may be a key step in protein misfolding and aggregation of TDP-43 
[13, 14].  
 
In a recent report, Zhang et al. showed that the ectopic expression of a ~25-kDa TDP-43 fragment corresponding to 
the C-terminal truncation product of caspase-cleaved TDP-43 leads to the formation of toxic, insoluble, and 
ubiquitin-positive cytoplasmic inclusions within human cell lines. In addition, by generating a conformation-
dependent antibody that detects C-terminal fragments, caspase-cleaved TDP-43 was identified in postmortem human 
brain sections in FTLD-U and ALS [12].  
 
We recently developed a site-directed caspase-cleavage antibody to TDP-43, termed TDPccp, and identified 
caspase-cleaved TDP-43 in several tauopathies including AD and Pick’s disease [7, 11]. Specifically, caspase-
cleaved TDPccp was identified within Hirano bodies in CA1 region of the hippocampus in AD and Pick’s disease 
suggesting this might be a common feature of tauopathies [7, 11]. These findings support the conclusion that the 
presence of TDP-43 pathology is not solely restricted to TDP-43 proteinopathies, but may be more widely 
distributed in a number of neurodegenerative diseases [13]. The purpose of the present study was to determine a 
possible role for caspase-cleaved TDP-43 in PD and DLB, neurodegenerative disorders classified as alpha-
synucleinopathies.   
 
PD and DLB are clinically characterized by progressive dementia and/or motor syndromes and exhibit widespread 
neuronal cell loss. In PD, patients develop extrapyramidal movement disturbances [15] and the diagnosis is based on 
presence of two of the three following clinical features: bradykinesia, resting tremor and rigidity [16]. The 
pathological hallmark of idiopathic PD is loss of dopaminergic neurons from the substantia nigra [15]. In DLB, 
several groups have recognized distinctive clinical features including impairment of attention, problem solving, and 
visuospatial skills associated with loss of neurons from the cortex [17, 18]. Microscopically, in PD and DLB cell 
loss is associated with the presence of Lewy body inclusions that are comprised principally of aggregated alpha-
synuclein (α-Syn) [19]. 
 
In the present study, application of our site-directed caspase-cleavage antibody to TDP-43 in postmortem brain 
sections from PD and DLB revealed the presence of caspase-cleaved TDP-43 in Lewy bodies of all cases examined. 
Co-localization of TDPccp with an antibody to α-Syn was evident within the substantia nigra in both alpha-
synucleinopathies. Interestingly, the TDPccp antibody detected on average roughly twice the number of Lewy 
bodies compared to the α-Syn antibody. Collectively, these data have identified caspase-cleaved TDP-43 as a 
primary component of Lewy bodies in PD and DLB, and suggest the TDPccp antibody is an effective marker for the 
detection of Lewy bodies. 
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Materials and Methods – 
 
Antibodies  
 
The monoclonal mouse α-Syn antibody (clone LB509) was purchased from Zymed (San Francisco, CA). The 
caspase-cleavage product antibody to TDP-43 (TDPccp) was an in house antibody that has previously been shown 
to be a specific marker for caspase-cleaved TDP-43 [7]. This antibody was synthesized based upon a putative 
caspase cleavage consensus site (DVMD219) within TDP-43. 
 
Human subjects  
 
Autopsy brain tissue from five neuropathologically confirmed Parkinson’s cases and five confirmed dementia with 
Lewy bodies cases was studied. Human brain tissues used in this study were provided by the Institute for Memory 
Impairments and Neurological Disorders at the University of California, Irvine.  
 
Immunohistochemistry and immunofluorescence microscopy 
 
For immunohistochemical and immunofluorescence studies, free-floating 40 µm-thick serial sections from PD and 
DLB subjects were used as previously described [20, 21]. Antibody dilutions were 1:100 for TDPccp and 1:500 for 
mAb α-Syn. For single labeling, antigen visualization was accomplished using ABC complex (ABC Elite 
immunoperoxidase kit, Vector labs), followed by brown/red DAB substrate (Vector Labs). For immunofluorescence 
co-localization studies, antigen visualization was accomplished using an Alexa fluor 488-labeled tyramide (green, 
Ex/Em = 495/519) for the first label and streptavidin Alexa Fluor 555 (red, Ex/Em = 555/565) for the second label, 
both purchased from Invitrogen (Carlsbad, CA). 
 
Western blot analysis 
 
Human brain lysates from DLB and age-matched control subjects were processed for Western blot analysis as 
previously described [21]. Proteins were separated by 12% SDS-PAGE and transferred to nitrocellulose. To verify 
equal loading between samples, transferred slabs were stained in coomassie blue. Membranes were incubated in 
TDPccp and primary antibody was visualized with a goat anti-rabbit HRP-linked secondary antibody (1:5,000; 
Jackson’s Laboratory, West Grove, PA), followed by ECL detection. Protein content from all the samples was 
analyzed using the BCA assay (Pierce) to ensure equal protein loading. In addition, Western blot analysis was 
performed utilizing a beta-actin antibody (1: 400) as a loading control.  
 
Quantification and statistical analysis  
 
A semi-quantitative analysis was performed by first taking 20X immunofluorescence, overlapping images (labeled 
with both TDPccp and a-Syn) from the substantia nigra area in five separate Parkinson’s and five DLB cases. 
Photographs were then analyzed by counting the number of Lewy bodies and calculating the percent of inclusion 
bodies labeled for either α-Syn or TDPccp antibodies in the entire tissue section for each case. Data were than 
averaged ±S.E.M. Additionally, α-Syn labeling was utilized as a general marker for Lewy bodies and compared with 
the number of α-Syn-labeled Lewy bodies that co-localized with TDPccp.  Statistical difference between percentage 
of α-Syn single-labeled, TDPccp single-labeled and α-Syn-TDPccp double-labeled Lewy Bodies was analyzed by 1-
way ANOVA (GLM procedure with contrast statement) with statistical significance established at a p-value < 0.05. 
Data were normally distributed with no significant difference in variances across the antibody classes. The 
calculations were performed using a SAS program version 9.1.3 Service Pack 3 for Windows XP-Pro. 
 
Results –  
 
A critical feature of TDP-43 proteinopathies is the presence of cytoplasmic C-terminal fragments of TDP-43 (~25 
and 35 kDa) that have ability to aggregate [22]. One candidate protease that may be involved in the proteolytic 
processing of TDP-43 is caspase-3.  Zhang et al. have shown in vitro that TDP-43 is a substrate for caspase-3 
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leading to the generation of 25 and 35 kDa species [23]. The goal of the present study was to examine whether 
caspase-cleaved TDP-43 is a relevant finding in the PD and DLB brain.  
 
Five confirmed cases of PD and DLB were examined by immunohistochemistry utilizing our site-directed caspase-
cleaved antibody to TDP-43, termed TDPccp. As an initial approach, immunoreactivity to TDPccp was assessed in 
two different brain regions including the substantia nigra and hippocampus. Application of the TDPccp antibody 
using bright-field microscopy revealed caspase-cleaved TDP-43 labeling in the SN region within Lewy bodies 
(arrowheads, Fig. 1, A and B). In hippocampal sections, caspase-cleaved TDP-43 was found in Lewy bodies and 
within Hirano bodies in both diseases (arrows, Fig. 1, C and D).  To confirm the immunohistochemical results, 
Western blot analysis was carried out using the TDPccp antibody. The results confirmed the presence of the 
predicted caspase-cleaved fragment of TDP-43 ( 25 kDa) in all four DLB cases examined (Fig. 2).  As shown, the 
antibody also recognized a fainter band in DLB subjects running at 35 kDa.  This may represent an additional 
caspase-cleaved fragment of TDP-43 as a previous study has shown that caspase cleavage of TDP-43 results in the 
generation of both 35 kDa and 25 kDa fragments [12].  There was no immunoreactivity observed at 43 kDa 
corresponding to full-length TDP-43 in any of the samples analyzed (control or DLB), suggesting a lack of 
immunoreactivity of TDPccp to full-length TDP-43. 
 
A common pathological feature of PD and DLB is the presence of α-Syn, and numerous studies employ the use of a 
full-length antibody to α-Syn as a general marker for Lewy bodies.  We examined the extent of co-localization of 
TDPccp with a well-characterized full-length antibody to α-Syn (LB509, Zymed Labs).  Immunofluorescence 
double-labeling experiments indicated a colocalization of both antibodies within Lewy bodies in PD and DLB (Fig. 
3). Of interest was the relative uniform distribution of α-Syn and TDPccp labeling within Lewy bodies in PD, while 
in DLB both α-Syn and the TDPccp labeling appeared to be more peripherally distributed. These findings confirmed 
the presence of caspase-cleaved TDP-43 within Lewy bodies in PD and DLB.  Although co-localization was evident 
within the SN of both diseases, single-labeling of Lewy bodies with either antibody was also evident (Fig. 4).  
Moreover, it appeared more Lewy bodies were singly labeled with TDPccp than with the α-Syn antibody (Fig. 4).  
Quantification experiments indicated that the majority of Lewy bodies identified within SN brain sections were 
labeled with both TDPccp and the α-Syn antibody (blue bars, Fig. 5).  However, quantification of the number Lewy 
bodies labeled by α-Syn and TDPccp antibodies in PD and DLB cases revealed the average percent of caspase-
cleaved TDP-43 single-labeled Lewy bodies was approximately twice the percent that of α-Syn labeling in both 
alpha-synucleinopathies (Fig. 5A: 13.4% vs. 5.5% in DLB, Fig. 5B: 34.6% vs. 17.6% in PD). Statistical differences 
between the percentages of α-Syn single-labeled, TDPccp single-labeled and α-Syn-TDPccp double-labeled Lewy 
Bodies was analyzed by 1-way ANOVA (GLM procedure with contrast statement) with statistical significance 
established at a p-value < 0.05. Data were normally distributed with no significant difference in variances across the 
antibody classes. For DLB, the overall F2, 12 was 284.07 with the p-value* < 0.05 and for PD, the overall F2, 12 was 
26.41 with the p-value* < 0.05.  
 
Discussion –  
 
TDP-43 has been identified as a major component of ubiquitinated tau-negative inclusions in sporadic FTLD-U and 
ALS [3]. For this common pathology, FTLD-U and ALS are now grouped together as a new entity of 
neurodegenerative disorders, classified as TDP-43 proteinopathies [24]. Recent advances have suggested a key event 
that may promote disease progression in TDP-43 proteinopathies is the redistribution of truncated forms of TDP-43 
from the nucleus to the cytoplasm [25]. In support of this hypothesis are data demonstrating the presence of smaller 
(~25 kDa) phosphorylated fragments of TDP-43 in brain samples from both FTLD-U and ALS [26].  These findings 
suggest that post-translational modification of TDP-43 may signal a shift to a toxic gain of function.  One candidate 
protease that may be involved in the proteolytic processing of TDP-43 is caspase-3. Zhang et al. have shown that 
TDP-43 is a substrate for caspase-3 leading to the generation of 25 and 35 kDa species [23]. Our lab has also 
supported the hypothesis that caspases may play a major role in the processing of TDP-43 in other 
neurodegenerative disorders: utilizing a site-directed caspase-cleavage antibody to a known consensus cleavage site 
within TDP-43 (DVMD219), we identified caspase-cleaved TDP-43 in two tauopathies, AD and Pick’s disease [7, 
11]. Specifically, caspase-cleaved TDP-43 was identified within Hirano bodies in CA1 region of the hippocampus in 
AD and Pick’s disease.   
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These findings support the conclusion that the presence of caspase-cleaved TDP-43 is not solely restricted to TDP-
43 proteinopathies, but may be more widely distributed in a number of neurodegenerative diseases. Thus, to confirm 
and extend these findings, our goal in the present study was to examine whether caspase-cleaved TDP-43 is a 
relevant finding in PD and DLB, collectively known as α-synucleinopathies. In PD and DLB, neurodegeneration is 
believed to be associated with the presence of intraneuronal inclusions termed Lewy bodies that are composed of α-
synuclein [27]. Numerous studies support the hypothesis that α-synuclein aggregation is the key step driving 
pathology, cellular damage, and subsequent neuronal dysfunction [28-31]. In the present study, we examined 
whether an accumulation of caspase-cleaved TDP-43 is a major finding associated with these α-synucleinopathies. 
 
Five confirmed cases of PD and DLB were examined by immunohistochemistry utilizing our site-directed caspase-
cleaved antibody to TDP-43, termed TDPccp. As an initial approach, immunoreactivity to TDPccp was assessed in 
two different brain regions including the substantia nigra and hippocampus. Application of the TDPccp antibody 
using bright-field microscopy revealed the presence of caspase-cleaved TDP-43 within Lewy bodies in the SN of 
DLB and PD samples. In hippocampal sections, caspase-cleaved TDP-43 was found in Lewy bodies and within 
Hirano bodies in both diseases. Hirano bodies are characterized as rod-shaped, paracrystalline structures in the 
neurons of the central nervous system and are commonly found in numerous neurodegenerative diseases within the 
CA1 region of the hippocampus [32]. These results parallel our findings of caspase-cleaved TDP-43 within Hirano 
bodies in AD and Pick’s disease [7, 11] and support a general role for caspase activation and cleavage of TDP-43 
within these eosinophilic structures.   It is important to note that although structures labeled by our TDPccp antibody 
morphologically resembled Hirano bodies, no experiments were carried out to confirm this finding using specific 
markers to Hirano bodies.  Therefore, further studies will be necessary to confirm the finding of caspase-cleaved 
TDP-43 within these structures.  
 
A central feature of TDP-43 proteinopathies is the presence of cytoplasmic fragments of TDP-43 (~25 and 35 kDa) 
that have ability to aggregate [22]. Current understanding suggests that the 25 kDa TDP-43 fragment corresponding 
to the truncation product of caspase-cleaved TDP-43 leads to a toxic gain of function. For example, caspase 
cleavage of TDP-43 is a critical step leading to the aggregation and redistribution of TDP-43 from the nucleus to the 
cytoplasm [12].  In addition, a recent study by Johnson et al. has demonstrated that only aggregating forms of TDP-
43 are toxic [33].  Therefore, post-translational proteolytic processing of TDP-43 by caspases may be a key step in 
protein misfolding, aggregation and toxicity of TDP-43 in ALS and FTLD-U [13, 14]. Our data showing the 
presence of caspase-cleaved TDP-43 (~25 kDa fragment) within Lewy bodies extends these findings to α-
synucleinopathies. 
 
A common pathological feature of PD and DLB is the presence of α-Syn, and numerous studies employ the use of a 
full-length antibody to α-Syn as a general marker for Lewy bodies.  We examined the extent of co-localization of 
TDPccp with a well-characterized full-length antibody to α-Syn (LB509, Zymed Labs).  Immunofluorescence 
double-labeling experiments indicated a colocalization of both antibodies within Lewy bodies in PD and DLB, 
thereby confirming the presence of caspase-cleaved TDP-43 within Lewy bodies in PD and DLB.  Quantification 
experiments indicated that the majority of Lewy bodies identified within SN brain sections were labeled with both 
TDPccp and the α-Syn antibody.  However, a small percentage of Lewy bodies were found that were only labeled 
with either TDPccp or the α-Syn antibody, respectively. Quantification of the number Lewy bodies single-labeled by 
TDPccp was approximately twice the percent that of the full-length α-Syn antibody in both α-synucleinopathies. 
Statistical differences were detected between the percentages of α-Syn single-labeled, TDPccp single-labeled and α-
Syn-TDPccp double-labeled Lewy Bodies by 1-way ANOVA (GLM procedure with contrast statement) with 
statistical significance established at a p-value < 0.05. The identification of Lewy bodies that only labeled with 
TDPccp and are alpha-synuclein-negative can be interpreted in several ways.  One interpretation is the existence of 
Lewy bodies in the absence of α-Syn pathology.  Although possible, and in fact previously reported [34] these 
structures probably represent a minority of total number of Lewy bodies present following tissue analysis. A more 
likely interpretation of our data is the presence of Lewy bodies that labeled with TDPccp, but had insufficient levels 
of α-Syn to be detected by the α-Syn antibody at the titer employed (1:500).  In either case, out data clearly show 
that the majority of Lewy bodies identified contain both α-Syn and caspase-cleaved TDPccp. 
 
In conclusion, results from the present study identify caspase-cleaved TDP-43 as a primary component of Lewy 
bodies in α-synucleinopathies, and suggest the TDPccp antibody is an effective marker for the detection of Lewy 
bodies. Future studies are necessary, however, to address whether the presence of caspase-cleaved TDP-43 in α-
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synucleinopathies is a cause or effect of the underlying pathological events associated with these neurodegenerative 
diseases. 
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Figure legends - 
Figure 1. Caspase-cleaved TDP-43 in PD and DLB. Representative bright-field single labeling utilizing the 
TDPccp antibody from a Parkinson’s case (A, C) and Dementia with Lewy Bodies case (B, D). Application of the 
TDPccp antibody revealed labeling in the SN region within Lewy bodies (arrowheads, A and B) and in the CA1 
region of the hippocampus within Hirano bodies (arrows, C and D) as well as Lewy bodies (arrowheads, C and D). 
All scale bars represent 10 µm. 
 
Figure 2. Western blot analysis utilizing the TDPccp antibody in representative DLB or control cases. 
Western blot analysis using the TDPccp antibody confirmed the presence of the predicted caspase-cleaved fragment 
TDP-43 ( 25 kDa) in all four DLB cases. Bottom panel represents the same blot stripped and reprobed with a β-actin 
antibody, which served as a loading control. Data are representative of three independent experiments. 
 
Figure 3. Caspase-cleaved TDP-43 co-localizes with alpha-synuclein within Lewy bodies in PD and DLB. Full-
length α-Syn and caspase-cleaved TDP-43 antibodies co-localized within Lewy bodies in PD (A-C) and DLB (D-F). 
Representative immunofluorescence double-labeling employing an α-Syn monoclonal antibody (green, A and D) 
and TDPccp (red, B and E) and the overlap image for both markers (yellow, C and F). Note the relative uniform 
distribution of α-Syn and TDPccp labeling within the Lewy body in PD case (C), while in DLB case both α-Syn and 
the TDPccp appear to be more peripherally distributed (F). All scale bars represent 10 µm. 
 
Figure 4. The TDPccp antibody detects a greater number of Lewy bodies in PD and DLB than the 
standardized marker, alpha-synuclein. A-C: Representative immunofluorescence double-labeling utilizing the α-
Syn antibody (green), TDPccp (red) and the overlap image (C). D-F: Identical to Panels A-C showing α-Syn 
labeling (green), TDPccp (red), and the overlap image for both markers within a Lewy body (arrowhead, F). Note 
the greater number of caspase-cleaved TDP-43-labeled Lewy bodies compared to full-length α-Syn-labeled Lewy 
bodies in SN in both alpha-synucleinopathies (arrows, C and F). A-C: Scale bars represent 10 µm; D-F: Scale bars 
represent 20 µm. 
 
Figure 5. Caspase-cleaved TDP-43 as a primary marker for Lewy bodies in DLB and PD. Quantification of 
Lewy bodies labeled by α-Syn and TDPccp antibodies. A monoclonal antibody to α-Syn was utilized as a marker for 
Lewy bodies. Data show the average percent of Lewy bodies labeled with α-Syn, TDPccp, and with both antibodies 
in SN of DLB cases (A) and PD cases (B) (percent given above bars) ± S.E.M. Note in both alpha-synucleinopathies 
the percent of caspase-cleaved TDP-43 single-labeled Lewy bodies is approximately twice the percent that of full-
length α-Syn labeling. Data represent the average percent of Lewy bodies (±S.E.M.) in whole sections from five 
representative DLB cases (A, overall F2, 12 = 284.07, p-value* < 0.05) and five Parkinson’s cases (B, overall F2, 12 = 
26.41, p-value* < 0.05). 
 
